Drug makers’ downsizing moves continue unabated in Japan. In the past three months alone, it was revealed that voluntary redundancy programs were being planned or launched for Pfizer, MSD, and Sanofi, affecting a total of over 600 staffers mainly in…
HOME > REGULATORY
REGULATORY
- AbbVie’s Venetoclax Up for Review on Aug. 23; Tecentriq’s Breast Cancer Use, 2nd Biosimilars Also on Agenda
August 16, 2019
- Japan OKs Zetia Generic, Possibly AG, towards December Listing; No Entry for Lyrica This Time
August 16, 2019
- MHLW to Announce New Drug Prices on Aug. 19
August 9, 2019
- MHLW Gives Update on Heptavax, Seeks Cooperation in Stable Hep B Vaccine Supplies
August 8, 2019
- MHLW Compliance Chief Stresses Priorities on PMD Law Amendment, Steady Implementation of Detailing Guidelines
August 8, 2019
- MHLW Begins Discussions on Clinical Use of Human-Embryo Gene Editing
August 5, 2019
- MHLW Pharma Bureau Chief Keen on Early Enactment of PMD Amendment Bill
August 5, 2019
- Tecentriq’s SCLC Use Gets MHLW Panel Nod for September Approval
August 5, 2019
- Cost-Effectiveness Challenge Remains in Adding Rotavirus Vaccine to Public Vaccination Programs: MHLW Panel
August 5, 2019
- Nobelpharma’s Tympanic Membrane Perforation Drug Clears MHLW Panel, September OK Likely
August 2, 2019
- MHLW Finalizing Timing to Announce Post-Oct. 1 NHI Prices, Bureau Chief Hints at August Possibility
August 2, 2019
- Japan OKs FY2020 Budget Guidelines, Sets 530 Billion Yen Request Ceiling for Social Security Cost Rise
August 1, 2019
- Indonesia to Shorten Review Period for Japan-Approved Drugs
July 29, 2019
- Chuikyo to Revisit Generic Price-Band Rule
July 26, 2019
- Apply Essential Drug Price Maintenance Rule Soon after Unprofitability Re-Pricing: FPMAJ
July 25, 2019
- Chuikyo Wraps Up 1st Round of Discussions on 2020 Medical Fee Revision
July 25, 2019
- Chuikyo Cautious about Considering Societal Values in New Drug Pricing
July 25, 2019
- Don’t Cause Confusion in Drug Distribution in Tax-Linked Drug Re-Pricing: JPWA
July 25, 2019
- Industry’s Plea to Scrap PMP Company Criteria Gets Cold Shoulder at Chuikyo
July 25, 2019
- Regenerative Medicine Forum Opposes Lower Premium Rates for Cell & Gene Therapies, Wins Chuikyo Support for New Pricing Scheme
July 24, 2019
ページ
As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In my home country of Australia, there is a famous candy called “Minties”. Minties has a long-running advertising campaign, presenting comical situations, with the caption, “It’s moments like these.” The phase has become part of the Aussie vernacular, meaning in…